JP2004537581A5 - - Google Patents

Download PDF

Info

Publication number
JP2004537581A5
JP2004537581A5 JP2003518580A JP2003518580A JP2004537581A5 JP 2004537581 A5 JP2004537581 A5 JP 2004537581A5 JP 2003518580 A JP2003518580 A JP 2003518580A JP 2003518580 A JP2003518580 A JP 2003518580A JP 2004537581 A5 JP2004537581 A5 JP 2004537581A5
Authority
JP
Japan
Prior art keywords
acid
alanine
arginine
derivative
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003518580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/026796 external-priority patent/WO2003013574A1/en
Publication of JP2004537581A publication Critical patent/JP2004537581A/ja
Publication of JP2004537581A5 publication Critical patent/JP2004537581A5/ja
Pending legal-status Critical Current

Links

JP2003518580A 2001-08-08 2002-08-02 メラニン濃縮ホルモン拮抗物質 Pending JP2004537581A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31092801P 2001-08-08 2001-08-08
PCT/US2002/026796 WO2003013574A1 (en) 2001-08-08 2002-08-02 Melanin-concentrating hormone antagonists

Publications (2)

Publication Number Publication Date
JP2004537581A JP2004537581A (ja) 2004-12-16
JP2004537581A5 true JP2004537581A5 (enExample) 2005-12-22

Family

ID=23204651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518580A Pending JP2004537581A (ja) 2001-08-08 2002-08-02 メラニン濃縮ホルモン拮抗物質

Country Status (5)

Country Link
US (1) US7335723B2 (enExample)
EP (1) EP1416951A1 (enExample)
JP (1) JP2004537581A (enExample)
CA (1) CA2456964A1 (enExample)
WO (1) WO2003013574A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2017069269A1 (ja) * 2015-10-23 2017-04-27 富士フイルム株式会社 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤
SG11201803001WA (en) 2015-10-23 2018-05-30 Fujifilm Corp Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
JP2023505687A (ja) 2019-12-11 2023-02-10 インスピルナ,インコーポレーテッド 癌の処置方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049655A (en) 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
EP1255770A4 (en) 2000-02-03 2004-12-08 Merck & Co Inc ANALOGS OF MELANINE CONCENTRATING HORMONE
CA2449004A1 (en) 2001-05-31 2002-12-05 Merck & Co., Inc. Melanin-concentrating hormone analogs
US7273846B2 (en) 2002-01-09 2007-09-25 Merck & Co., Inc. Selective melanin-concentrating hormone type-1 receptor agonists

Similar Documents

Publication Publication Date Title
JP2010536714A5 (enExample)
JP2013155195A5 (enExample)
JP2013533864A5 (enExample)
KR970042553A (ko) 캠프토테신 유도체
KR101328851B1 (ko) 개선된 특성을 가지는 재구성된 계면활성제
JP2011511753A5 (enExample)
JP2004521123A5 (enExample)
JP2006514104A5 (enExample)
JP2002526454A5 (enExample)
RU2008141280A (ru) Агонисты рецептора нейромедина u и их применение
JP2015532283A5 (enExample)
JP2013500990A5 (enExample)
JP2023537951A5 (enExample)
JP2011508742A5 (enExample)
JP2007523881A5 (enExample)
CA2121724A1 (en) Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
JP2018504901A5 (enExample)
JP2024520861A (ja) 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
EP3074032B1 (en) Fatty acid derivatives of dimeric inhibitors of psd-95
JP2011523935A5 (enExample)
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
JPH0773479B2 (ja) 栄養素組成物
JP7809117B2 (ja) Glp-1/glp-2デュアルアゴニストの医薬組成物
JP2009533355A5 (enExample)
JP2004535461A5 (enExample)